Recent

% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • quantum_duck quantum_duck Nov 14, 2012 6:20 PM Flag

    Exclusivity, NCEs patents, generics..

    what are your thoughts on an appeal by, say, Glaxo, of the NCE, if granted ? who hears the appeal ? is it expensive ? how long may it take ??

    thanks in advance…keep up the good work

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • GSK doesn't have a case, since Lovaza's "moiety" is NOT the EPA molecule. It is BOTH the EPA and the DHA molecules.

      (Of course, GSK could try to prove Lovaza's "moiety" is JUST the EPA molecule alone; but that will take some time. And the giant might also have to do away with the DHA molecule in its pill, literally, or medicinally declaring it to be an non-active ingredient... then, yes, Lovaza would be just another Vascepa.)

      But Vascepa's "moiety" is just the EPA molecule alone. There is actually a good reason why introductory logic needs to be taught in all colleges.

 
AMRN
2.94+0.24(+8.89%)Sep 23 4:00 PMEDT